Applied Clinical Trials
New ASCO study evaluating the cancer care system reveals mixed findings.
A new study by the American Society of Clinical Oncology (ASCO) chronicles the current realities of the cancer care system and examines trends in the oncology workforce and practice environment that are affecting patient care and access. The report is titled "The State of Cancer Care in America: 2015."
According to the ASCO report, there is a wider array of treatment options than ever before for many cancers. In 2014, the FDA added 10 new treatments to its list of more than 170 approved anti-cancer agents, and also approved four new medical devices and tests that may improve patient outcomes through early detection of cancer. In addition, more than 770 cancer therapies are in the research and development pipeline and therapies are demonstrating dramatic improvements in efficacy.
However, the report noted growing challenges to high-quality care delivery, some are as follows:
ASCO made several recommendations directed to Congress, one of which calls on increasing the budgets of the National Institutes of Health and the National Cancer Institute by at least $32 billion and $5.32 billion, respectively. View the full release here: http://bit.ly/1y2htXm.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity
May 16th 2025In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy frequency in patients with narcolepsy type 1, outperforming current therapies and avoiding liver toxicity seen with earlier OX2R agonists, according to results published in The New England Journal of Medicine.